XPC gene variants: a risk factor for recurrence of urothelial bladder carcinoma in patients on BCG immunotherapy

  • Ruchika Gangwar
  • Anil Mandhani
  • Rama Devi Mittal
Original Paper

DOI: 10.1007/s00432-009-0717-y

Cite this article as:
Gangwar, R., Mandhani, A. & Mittal, R.D. J Cancer Res Clin Oncol (2010) 136: 779. doi:10.1007/s00432-009-0717-y
  • 136 Downloads

Abstract

Purpose

To investigate the association between two Xeroderma pigmentosum group C polymorphism (XPC Lys939Gln and insertion/deletion PAT −/+ in intron 9) and bladder cancer (BC) susceptibility.

Materials and methods

Genotyping was performed in 208 BC patients and 245 controls by PCR–RFLP method.

Results

XPC PAT +/+ genotype was associated with elevated risk of BC (p = 0.021, OR = 2.49). XPC Lys939Gln AC + CC genotype was significantly associated with risk in invasive stage of BC (p = 0.041, OR = 2.52). Haplotype analysis revealed that variant genotypes C of XPC Lys939Gln and + of PAT, C+ were significantly associated with risk of BC (p = 0.004, OR = 1.70). The CC genotype of Lys939Gln was associated with high risk for recurrence in BCG-treated patients (HR = 3.21, p = 0.036) thus, showing reduced recurrence-free survival (AC + CC/AA = 36/60 months; log rank p = 0.045).

Conclusion

Polymorphisms and haplotypes in XPC appear to influence susceptibility to BC risk. The variant C allele at Lys939Gln may be responsible for early recurrence in BCG-treated patients.

Keywords

Bladder cancer Bacillus Calmette–Guerin DNA repair Polymorphism Recurrence XPC 

Abbreviations

XPC

Xeroderma pigmentosum group C

BCG

Bacillus Calmette–Guerin

BC

Bladder cancer

MMC

Mitomycin-C

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Ruchika Gangwar
    • 1
  • Anil Mandhani
    • 1
  • Rama Devi Mittal
    • 1
  1. 1.Department of Urology and Renal TransplantationSanjay Gandhi Post Graduate Institute of Medical Sciences (SGPGIMS)LucknowIndia

Personalised recommendations